Medirazin (Alfacalcidol)

Alfacalcidol is converted in the liver to calcitriol, the active form of vitamin D3. Calcitriol binds to vitamin D receptors in the intestinal lining, stimulating the synthesis of calcium‑binding proteins and increasing absorption of calcium and phosphate. It also influences bone cells to promote balanced remodeling.

The dosage of Medirazin is individualized. A qualified prescriber determines the appropriate strength and frequency based on the patient’s specific condition, laboratory values, and response to therapy. No standard dose is provided here.

Safety data for Alfacalcidol in pregnancy and lactation are limited. The product is classified as pregnancy category unknown, and it should only be used if the potential benefit justifies any possible risk to the fetus or infant. Consultation with a healthcare professional is essential.

To order Medirazin, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Alfacalcidol is a synthetic analogue that requires hepatic conversion to calcitriol, whereas calcitriol is the active form administered directly. Alfacalcidol may offer more convenient dosing in patients with mild liver function, but both agents share similar efficacy in raising calcium levels and carry comparable safety profiles.

Medirazin should be stored at ambient temperature below 25°C. Keep the product in its original packaging, protect it from moisture and direct light, and ensure the container is tightly closed to maintain stability throughout its shelf life.

Medirazin is taken orally, usually with or without food as directed by the prescribing clinician. Swallow the tablet whole with a glass of water and follow any specific instructions regarding timing relative to meals or other medications.

The most serious risks include hypercalcemia, which can cause cardiac arrhythmias, renal impairment or nephrolithiasis, and rare cases of severe allergic reactions. Patients should be monitored regularly for serum calcium and phosphate levels, and any symptoms such as muscle weakness, confusion or severe abdominal pain should prompt immediate medical evaluation.

Medirazin is contraindicated in individuals with known hypersensitivity to Alfacalcidol or any excipients, and in patients with severe hypercalcemia or active hyperparathyroidism. Caution is also advised for those with severe renal impairment, sarcoidosis, or granulomatous diseases, where vitamin D metabolism may be altered.